Markets

UPDATED: Trevena prices upsized IPO at $7, as expected

Trevena, a clinical-stage biotech developing treatments for pain and acute heart failure, raised $65 million by offering 9.3 million shares at $7, as expected. Prior to postponing its IPO in November 2013, the company had been looking to raise $75 million at a price range of $12 to $14. Trevena plans to list on the NASDAQ under the symbol TRVN. Trevena initially filed confidentially on 9/6/2013. Barclays and Jefferies & Co. acted as joint bookrunners on the deal.

UPDATE: Trevena changed its pricing terms Friday morning. It had previously announced that it was offering 8.5 million shares.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TRVN

Other Topics

IPOs

Latest Markets Videos